Stephan Babirak, MD
Endocrinology, Diabetes & Metabolism · Scarborough, MENPI 1689619884
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $618,889 of the $802,275 with a category attached, or 77.1%. 52 manufacturers reported payments, led by Lilly USA, LLC at 32.3% of the total. Reporting peaked in 2019 at $161,137 and has fallen 53.2% since, to $75,357 in 2025.
Across 1,870 payments — averaging $429.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$259K
- Novo Nordisk$241K
- Boehringer Ingelheim$79K
- Kaneka Medical America LLC$55K
- AbbVie$36K
- Amgen$28K
- plus $105K from 46 others
What the payments were for
- Consulting fees$52,8427%
- Speaking & faculty fees$618,88977%
- Travel & lodging$93,90812%
- Food & beverage$36,0614%
- Education$5760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$182,476
- MOUNJARO$128,041
- Ozempic$127,697
- RYBELSUS$81,767
- LIPOSORBER$55,417
- Synthroid$27,300
- PRALUENT$27,087
- Repatha$25,769
- NEXLIZET$21,398
- NEXLETOL$21,398
- INVOKANA$13,939
- EVKEEZA$6,391
- FREESTYLE LIBRE 3$6,298
- FreeStyle Libre 2$5,228
- Tresiba$4,847
- REZDIFFRA$3,711
- FreeStyle Libre Pro$2,875
- Xultophy 100/3.6$2,690
- Kerendia$1,701
- InPen$620
How this compares
Too few endocrinology, diabetes & metabolism providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvkeezaEvinacumab-Dgnb | 14 | $861,761 |
| OzempicSemaglutide | 436 | $740,617 |
| JardianceEmpagliflozin | 365 | $532,759 |
| Repatha SureclickEvolocumab | 412 | $394,694 |
| MounjaroTirzepatide | 184 | $223,682 |
| Praluent PenAlirocumab | 120 | $101,174 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $64,903 |
| TrulicityDulaglutide | 34 | $63,495 |
| FarxigaDapagliflozin Propanediol | 52 | $62,878 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $56,415 |
| VascepaIcosapent Ethyl | 53 | $52,020 |
| JanuviaSitagliptin Phosphate | 32 | $47,431 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $45,347 |
| InvokanaCanagliflozin | 42 | $39,295 |
| KerendiaFinerenone | 30 | $38,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Evkeeza | $17,627 | $861,76114 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $240,619 | $781,397484 claims |
| Boehringer IngelheimJardiance | $78,920 | $532,759365 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $258,755 | $298,018276 claims |
| AstraZenecaFarxiga | $1,539 | $62,87852 claims |
| MerckJanuvia | $344 | $47,43132 claims |
| Johnson & JohnsonInvokana | $14,100 | $39,29542 claims |
| BayerKerendia | $2,401 | $38,55330 claims |
| AbbVieSynthroid | $35,813 | $34,650270 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $21,952 | $28,33735 claims |
| Sanofi-aventis U.S. LLCLantus | $9,178 | $6,44834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Maineon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Scarborough
- Jayachidambaram AmbalavananScarborough$733
- Jessica RockwellScarborough$703
- Khaled Al SibaiScarborough$121
- Jacob QuaytmanScarborough$121
- Rahfa Kurdi ZeriklyScarborough$51
- Roger RittmasterCamden$5K
- Shazia AhmadBangor$2K
- David HotellingPortland$694
- Mark HendersonBangor$564
- Ana Mendoza SalazarBangor$321
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.